WallStreetZenWallStreetZen

NASDAQ: MDGS
Medigus Ltd Stock

$4.87-0.27 (-5.25%)
Updated May 26, 2023
MDGS Price
$4.87
Fair Value Price
$20.78
Market Cap
$8.04M
52 Week Low
$4.02
52 Week High
$13.05
P/E
-0.81x
P/B
0.21x
P/S
0.08x
PEG
N/A
Dividend Yield
17.47%
Revenue
$91.86M
Earnings
-$9.82M
Gross Margin
15.7%
Operating Margin
-8.05%
Profit Margin
-10.7%
Debt to Equity
1.1
Operating Cash Flow
-$6M
Beta
0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MDGS Overview

Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MDGS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MDGS ($4.87) is undervalued by 76.59% relative to our estimate of its Fair Value price of $20.78 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MDGS ($4.87) is significantly undervalued by 76.59% relative to our estimate of its Fair Value price of $20.78 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MDGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more MDGS due diligence checks available for Premium users.

Be the first to know about important MDGS news, forecast changes, insider trades & much more!

MDGS News

Valuation

MDGS fair value

Fair Value of MDGS stock based on Discounted Cash Flow (DCF)
Price
$4.87
Fair Value
$20.78
Undervalued by
76.57%
MDGS ($4.87) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDGS ($4.87) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MDGS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.81x
Industry
751.36x
Market
54.23x

MDGS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.21x
Industry
3.87x
MDGS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MDGS's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MDGS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MDGS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$97.7M
Liabilities
$43.0M
Debt to equity
1.1
MDGS's short-term assets ($52.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDGS's short-term assets ($52.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDGS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
MDGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MDGS vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
MDGS$8.04M-5.35%-0.81x0.21x
CFMS$8.17M-0.91%-0.18x0.18x
RSLS$7.53M+3.64%-0.03x0.97x
SRGA$7.44M-7.11%-0.11x-0.39x
AEMD$7.12M+4.73%-0.42x0.41x

Medigus Stock FAQ

What is Medigus's quote symbol?

(NASDAQ: MDGS) Medigus trades on the NASDAQ under the ticker symbol MDGS. Medigus stock quotes can also be displayed as NASDAQ: MDGS.

If you're new to stock investing, here's how to buy Medigus stock.

What is the 52 week high and low for Medigus (NASDAQ: MDGS)?

(NASDAQ: MDGS) Medigus's 52-week high was $13.05, and its 52-week low was $4.02. It is currently -62.72% from its 52-week high and 21.11% from its 52-week low.

How much is Medigus stock worth today?

(NASDAQ: MDGS) Medigus currently has 24,661,470 outstanding shares. With Medigus stock trading at $4.87 per share, the total value of Medigus stock (market capitalization) is $8.04M.

Medigus stock was originally listed at a price of $2,711.99 in Aug 5, 2015. If you had invested in Medigus stock at $2,711.99, your return over the last 7 years would have been -99.82%, for an annualized return of -59.48% (not including any dividends or dividend reinvestments).

How much is Medigus's stock price per share?

(NASDAQ: MDGS) Medigus stock price per share is $4.87 today (as of May 26, 2023).

What is Medigus's Market Cap?

(NASDAQ: MDGS) Medigus's market cap is $8.04M, as of May 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Medigus's market cap is calculated by multiplying MDGS's current stock price of $4.87 by MDGS's total outstanding shares of 24,661,470.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.